In many patients, the sympathetic nervous system supports pain and other features of complex regional pain syndrome (CRPS). Accumulating evidence suggests that interleukin (IL)-6 also plays a role in CRPS, and that catecholamines stimulate production of IL-6 in several tissues. We hypothesized that norepinephrine acting through specific adrenergic receptors expressed on keratinocytes stimulates the production of IL-6 and leads to nociceptive sensitization in a rat tibial fracture/cast model of CRPS. Our approach involved catecholamine depletion using 6-hydroxydopamine or, alternatively, guanethidine, to explore sympathetic contributions. Both agents substantially reduced nociceptive sensitization and selectively reduced the production of IL-6 in skin. Antagonism of IL-6 signaling using TB-2-081 also reduced sensitization in this model. Experiments using a rat keratinocyte cell line demonstrated relatively high levels of b2-adrenergic receptor (b2-AR) expression. Stimulation of this receptor greatly enhanced IL-6 expression when compared to the expression of IL-1b, tumor necrosis factor (TNF)-a, or nerve growth factor. Stimulation of the cells also promoted phosphorylation of the mitogen-activated protein kinases P38, extracellular signal-regulated kinase, and c-Jun amino-terminal kinase. Based on these in vitro results, we returned to animal testing and observed that the selective b2-AR antagonist butoxamine reduced nociceptive sensitization in the CRPS model, and that local injection of the selective b2-AR agonist terbutaline resulted in mechanical allodynia and the production of IL-6 in the cells of the skin. No increases in IL-1b, TNF-a, or nerve growth factor levels were seen, however. These data suggest that in CRPS, norepinephrine released from sympathetic nerve terminals stimulates b2-ARs expressed on epidermal keratinocytes, resulting in local IL-6 production, and ultimately, pain sensitization.
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Introduction
The participation of the sympathetic nervous system (SNS) in complex regional pain syndrome (CRPS), once referred to as reflex sympathetic dystrophy, has long been appreciated. In 1916, Leriche proposed that sympathetic hyperactivity caused the development of posttraumatic CRPS, and he advocated surgical sympathectomy and sympathetic anesthetic nerve blocks for the treatment of this condition [28] . Sympathetic blocks are still a widely utilized treatment option for CRPS, but there is considerable controversy regarding the mechanisms by which SNS activity supports pain and the other components of CRPS [5] . Distal limb fracture is the most common cause of CRPS [7, 44, 56] , and we have developed a rat tibia fracture/cast immobilization model that at 4 weeks postfracture closely mimics the vascular, boney, nociceptive, and inflammatory changes observed in early CRPS [10, 59] . This model provides an opportunity to investigate the role of sympathetic signaling in persistent CRPS-like postfracture pain.
A large body of clinical evidence points to facilitated peripheral neurogenic inflammation, involving neuropeptides substance P (SP) and calcitonin gene-related peptide (CGRP), as contributing to some of the signs and symptoms of CRPS, including pain sensitization, warmth, and edema [2,22,27,57]. Again, the fracture/cast CRPS model has provided results consistent with
